Focus on Regulus Therapeutics Inc. (NASDAQ:RGLS)

931

Some 5 analysts have recommended on the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) so far and from them the equity has an average call of Overweight. But what does that indicate? It deciphers analysts? recommendations; shareholders should know that 1.00 – 1.24 implies that a stock is a BUY. Call of 1.75 – 2.24 implies that an equity is a HOLD. SELL recommendation is represented by numbers 2.75 – 3.00.

Let’s look into the technical of the stock

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

As for the price, analysts project that shares of Regulus Therapeutics Inc. will be trading around $4.75 in the next 12 months.

The stock price is influenced by the financial performance and represents investors opinion of its future. That being the case, shareholders should recall that Regulus Therapeutics Inc. posted EPS of $(0.38) in its recent quarter.

The firm recorded the EPS from sales of 18,000%, which increased -26.17% from a same period a year ago.

Analysts on the average are projecting Regulus Therapeutics Inc. to post EPS of $-0.28 in the ongoing quarter.

Does Regulus Therapeutics Inc. have the capacity to surpass expectations? Casting an eye on the firm?s liquidity position, you note that the firm generated net cash of $(18.68M) from its operations in the previous quarter, resulting in free cash flow of $(18.82M). Net change in cash came at $(52,000).

Furthermore, the firm’s asset position was $80.17M at the close of the latest quarter. But Regulus Therapeutics Inc. is carrying liabilities totaling $41.45M.

The firm ended the latest quarter with diluted due shares of 52.99M.

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (NASDAQ:RGLS), an innovative biopharmaceutical company. The agreement includes a broad range of discovery and development services to support Regulus programs targeting microRNAs.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.